Teriparatide Injection

  • Bone disorders

Teriparatide Injection Generic Name & Formulations

General Description

Teriparatide (recombinant) 250mcg/mL; soln for SC inj; contains m-cresol.

Pharmacological Class

Hormone (human parathyroid hormone, recombinant).

How Supplied

Single-patient-use pens (2.48mL)—1


Teriparatide Injection Indications


Postmenopausal osteoporosis in women who are at high risk for fracture. To increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture. Treatment of men and women with osteoporosis associated with sustained glucocorticoid therapy at high risk for fracture (see full labeling).

Teriparatide Injection Dosage and Administration


20mcg SC once daily into thigh or abdominal wall; may treat for up to 2 years.


Not established.

Teriparatide Injection Contraindications

Not Applicable

Teriparatide Injection Boxed Warnings

Boxed Warning

Potential risk of osteosarcoma.

Teriparatide Injection Warnings/Precautions


Increased baseline risk for osteosarcoma (eg, Paget's disease of bone, unexplained increased alkaline phosphatase, open epiphyses, prior skeletal radiation therapy), bone metastases, history of skeletal malignancies, metabolic bone disease, hypercalcemia or risk thereof (eg, hyperparathyroidism): not recommended. Urolithiasis. Hypercalciuria. Hepatic, renal, or cardiac disease. Pregnancy. Nursing mothers: not recommended.

Teriparatide Injection Pharmacokinetics

See Literature

Teriparatide Injection Interactions


Caution with digoxin (teriparatide-induced hypercalcemia increases risk of toxicity).

Teriparatide Injection Adverse Reactions

Adverse Reactions

Arthralgia, pain, nausea; transient orthostatic hypotension, hypercalcemia, hyperuricemia, inj site reactions.

Teriparatide Injection Clinical Trials

See Literature

Teriparatide Injection Note

Not Applicable

Teriparatide Injection Patient Counseling

See Literature